AAN and AHS Update Migraine Prevention Guidelines, Expanding Treatment Options
Event summary
- The American Academy of Neurology (AAN) and American Headache Society (AHS) issued an updated guideline on August 31, 2026, for migraine prevention medications in adults.
- The guideline includes recommendations on newer preventive treatments, expanding options for people with migraine.
- Preventive treatments are recommended for individuals experiencing four or more migraine days per month or if migraine affects their ability to work or complete daily tasks.
- The guideline is endorsed by the American Academy of Family Physicians and published in Neurology® and Headache journals.
The big picture
The updated guideline reflects advancements in migraine research and treatment options, addressing a condition that significantly impacts daily functioning and quality of life. With the endorsement of the American Academy of Family Physicians, the recommendations are likely to influence clinical practice broadly, potentially increasing the use of preventive medications in both neurological and primary care settings. The guideline's emphasis on personalized treatment options underscores the growing trend toward tailored medical approaches in neurology.
What we're watching
- Adoption Pace
- How quickly clinicians will integrate the updated guidelines into practice and whether this will lead to a significant shift in migraine prevention strategies.
- Treatment Efficacy
- The effectiveness of newer preventive treatments compared to established options and their impact on reducing migraine frequency and severity.
- Patient Access
- The availability and affordability of recommended medications, particularly for patients with chronic migraine.